CA Patent

CA3249515A1 — Liquid compositions

Assigned to Janssen Sciences Ireland ULC · Expires 2023-10-26 · 3y expired

What this patent protects

The invention relates to an aqueous composition comprising: (i) rilpivirine or a pharmaceutically acceptable salt thereof; (ii) a hyaluronidase; and (iii) 0.001-100 mg/mL of at least one excipient selected from the group consisting of: (a) cellulose or a derivative thereof, or a …

USPTO Abstract

The invention relates to an aqueous composition comprising: (i) rilpivirine or a pharmaceutically acceptable salt thereof; (ii) a hyaluronidase; and (iii) 0.001-100 mg/mL of at least one excipient selected from the group consisting of: (a) cellulose or a derivative thereof, or a pharmaceutically acceptable salt thereof; and/or (b) an amino acid. The invention also relates to further compositions, kits, and the use of the aqueous composition in the treatment or prevention of a HIV infection in a subject.

Drugs covered by this patent

Patent Metadata

Patent number
CA3249515A1
Jurisdiction
CA
Classification
—
Expires
2023-10-26
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Sciences Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.